Zanubrutinib and Pterostilbene Intervention in Acute Lymphoblastic Leukemia: An Action Mechanism Unveiled by Network Pharmacology and Machine Learning

Zanubrutinib, a BTK inhibitor, and pterostilbene, a natural anticancer compound, show potential in combination therapy for Acute Lymphoblastic Leukemia (ALL). Analyzing over 12,000 genes associated with ALL, key hub proteins like LYN, BTK, MYD88, and SYK were identified as crucial for leukemia progression. Pathway analyses revealed their role in immune signaling, including B-cell receptor signaling. Zanubrutinib and pterostilbene complement each other by targeting these pathways, inhibiting leukemia cell growth and promoting apoptosis. This study highlights the importance of network pharmacology and machine learning in developing optimized, targeted treatments for ALL.